The store will not work correctly when cookies are disabled.
2-isobutyl-10-methyl-3-p-tolylpyrimido[4,5-b]quinoline-4,5(3H,10H)-dione
ID: ALA4790909
PubChem CID: 85090321
Max Phase: Preclinical
Molecular Formula: C23H23N3O2
Molecular Weight: 373.46
Molecule Type: Unknown
Associated Items:
Names and Identifiers
Canonical SMILES: Cc1ccc(-n2c(CC(C)C)nc3c(c(=O)c4ccccc4n3C)c2=O)cc1
Standard InChI: InChI=1S/C23H23N3O2/c1-14(2)13-19-24-22-20(21(27)17-7-5-6-8-18(17)25(22)4)23(28)26(19)16-11-9-15(3)10-12-16/h5-12,14H,13H2,1-4H3
Standard InChI Key: FRTXYGKAPYWUDO-UHFFFAOYSA-N
Molfile:
RDKit 2D
28 31 0 0 0 0 0 0 0 0999 V2000
26.8916 -9.5281 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.8905 -10.3555 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.6052 -10.7682 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.6035 -9.1155 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.3188 -9.5245 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.3195 -10.3513 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.0348 -10.7622 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
29.0292 -9.1104 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.7450 -9.5176 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.7486 -10.3471 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.4676 -10.7569 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
31.1835 -10.3384 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.1759 -9.5057 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
30.4563 -9.0996 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.0248 -8.2855 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
30.4491 -8.2748 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
31.8811 -9.0875 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.5996 -9.4949 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.3096 -9.0763 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.3022 -8.2506 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.5789 -7.8452 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.8719 -8.2660 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.8964 -10.7447 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.9004 -11.5706 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.6137 -11.9777 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.1881 -11.9866 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.0121 -7.8303 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.0369 -11.5871 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
6 7 1 0
7 10 1 0
9 8 1 0
8 5 1 0
9 10 2 0
10 11 1 0
11 12 2 0
12 13 1 0
13 14 1 0
14 9 1 0
8 15 2 0
14 16 2 0
17 18 2 0
18 19 1 0
19 20 2 0
20 21 1 0
21 22 2 0
22 17 1 0
13 17 1 0
23 24 1 0
24 25 1 0
12 23 1 0
24 26 1 0
20 27 1 0
7 28 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 373.46 | Molecular Weight (Monoisotopic): 373.1790 | AlogP: 3.74 | #Rotatable Bonds: 3 |
Polar Surface Area: 56.89 | Molecular Species: NEUTRAL | HBA: 5 | HBD: ┄ |
#RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): ┄ | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: ┄ | CX Basic pKa: ┄ | CX LogP: 4.74 | CX LogD: 4.74 |
Aromatic Rings: 4 | Heavy Atoms: 28 | QED Weighted: 0.51 | Np Likeness Score: -0.92 |
References
1. Luderman KD,Jain P,Benjamin Free R,Conroy JL,Aubé J,Sibley DR,Frankowski KJ. (2021) Development of pyrimidone D1 dopamine receptor positive allosteric modulators., 31 [PMID:33221389] [10.1016/j.bmcl.2020.127696] |